CIMZIA Drug Insight

“CIMZIA Market Size, Forecast, and Drug Insight – 2032” report offers an in-depth analysis of boththe  market and emerging insights regarding  CIMZIA for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis (PsA) in the 7MM. A detailed picture of the CIMZIA in the 7MM, i.e., United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan for the study period 2019–2032 is provided in this report along with a detailed description of the CIMZIA. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the CIMZIA market forecast, analysis in the 7MM, descriptive analysis such as SWOT, analysts’ views, comprehensive overview of market competitors, and brief about emerging therapies.

Drug Summary

CIMZIA (Certolizumab pegol) is a recombinant, humanized antibody Fab' fragment, with specificity for human tumor necrosis factor alpha (TNFa), conjugated to an approximately 40 kDa polyethylene glycol (PEG2MAL40K). The “Fab” fragment is manufactured in E. coli and subsequently subjected to purification and conjugation to PEG2MAL40K, to generate certolizumab pegol. The Fab' fragment is composed of a light chain with 214 amino acids and a heavy chain with 229 amino acids. The molecular weight of certolizumab pegol is approximately 91 kilo Daltons.

In Europe, UCB’s biologic CIMZIA (certolizumab pegol), in combination with methotrexate (MTX), is indicated for the treatment of moderate to severe, active RA in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs), including MTX, has been inadequate. CIMZIA can be given as monotherapy in cases of intolerance to MTX or when continued treatment with MTX is inappropriate. CIMZIA, in combination with MTX, is also indicated for the treatment of severe, active, and progressive RA in adults not previously treated with MTX or other DMARDs.

In March 2021, UCB announced that it had received its Declaration of Conformity (CE) mark for its first-in-class electromechanical injection device, ava Connect. The CE Mark indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area (EEA). The ava Connect and its disposable dose-dispenser cartridge are used for self-injecting CIMZIA, and it is the first reusable device of its kind available for use with biologic treatment in rheumatology and dermatology in Europe.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the CIMZIA description, mechanism of action, dosage and administration, research and development activities in Rheumatoid Arthritis and Psoriatic Arthritis (PsA).
• Elaborated details on CIMZIA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the CIMZIA research and development activity in Rheumatoid Arthritis and Psoriatic Arthritis (PsA) details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around CIMZIA.
• The report contains forecasted sales of CIMZIA for Rheumatoid Arthritis and Psoriatic Arthritis (PsA) till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Rheumatoid Arthritis and Psoriatic Arthritis (PsA).
• The report also features the SWOT analysis with analyst views for CIMZIA in Rheumatoid Arthritis and Psoriatic Arthritis (PsA).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

CIMZIA Analytical Perspective by DelveInsight

In-depth CIMZIA Market Assessment

This report provides a detailed market assessment of CIMZIA in Rheumatoid Arthritis and Psoriatic Arthritis (PsA) in the 7MM, i.e., United States, EU4 and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

CIMZIA Clinical Assessment

The report provides the clinical trials information of CIMZIA for Rheumatoid Arthritis and Psoriatic Arthritis (PsA) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for Rheumatoid Arthritis and Psoriatic Arthritis (PsA) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence CIMZIA dominance.
• Other emerging products for Rheumatoid Arthritis and Psoriatic Arthritis (PsA) are expected to give tough market competition to CIMZIA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones and developmental activities provides the current development scenario of CIMZIA in Rheumatoid Arthritis and Psoriatic Arthritis (PsA).
• Our in-depth analysis of the forecasted sales data of CIMZIA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of CIMZIA in Rheumatoid Arthritis and Psoriatic Arthritis (PsA).

Key Questions

• What is the product type, route of administration, and mechanism of action of CIMZIA?
• What is the clinical trial status of the study related to CIMZIA in Rheumatoid Arthritis and Psoriatic Arthritis (PsA), and the study completion date?
• What are the key collaborations, mergers and acquisitions, licensing, and other activities related to the CIMZIA development?
• What are the key designations that have been granted to CIMZIA for Rheumatoid Arthritis and Psoriatic Arthritis (PsA)?
• What is the forecasted market scenario of CIMZIA for Rheumatoid Arthritis and Psoriatic Arthritis (PsA)?
• What are the forecasted sales of CIMZIA in the 7MM, including the United States, Europe, and Japan? 
• What are the other emerging products available in Rheumatoid Arthritis and Psoriatic Arthritis (PsA), and how are they giving competition to CIMZIA for Rheumatoid Arthritis and Psoriatic Arthritis (PsA)?
• Which are the late-stage emerging therapies under development for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis (PsA)?